NCT06947226View on ClinicalTrials.gov

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions

Solid Tumors

Interventions

DRUG

9MW2821

Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

DRUG

Other anti-cancer therapy

Subjects will receive other anticancer therapy as per protocol

Trial Locations (1)

451161

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT06947226 - A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter